melanomas resist t-cell therapy inflammation-induced reversible dedifferentiation 
adoptive cell transfer therapies acts cytotoxic t cells target melanocytic antigens can achieve remissions patients metastatic melanomas tumours frequently relapse12 hypotheses explaining acquired resistance acts include selection antigen-deficient tumour cell variants3- induction t-cell tolerance6 however lack appropriate experimental melanoma models far impeded clear insights underlying mechanisms establish effective act protocol genetically engineered mouse melanoma model recapitulates tumour regression remission relapse seen patients report unexpected observation melanomas acquire act resistance inflammation-induced reversible loss melanocytic antigens serial transplantation experiments melanoma cells switch differentiated dedifferentiated phenotype response t-cell-driven inflammatory stimuli identified proinflammatory cytokine tumour necrosis factor tnf-alpha crucial factor directly caused reversible dedifferentiation mouse human melanoma cells tumour cells exposed tnf-alpha poorly recognized t cells specific melanocytic antigens whereas recognition t cells specific non-melanocytic antigens unaffected even increased results demonstrate phenotypic plasticity melanoma cells inflammatory microenvironment contributes tumour relapse initially successful t-cell immunotherapy basis work propose future act protocols simultaneously target melanocytic non-melanocytic antigens ensure broad recognition differentiated dedifferentiated melanoma cells include strategies sustain t-cell effector functions blocking immune-inhibitory mechanisms tumour microenvironment 
